Genotropin Treatment In Very Young Children Born Small For Gestational Age

Infant, Small for Gestational Age Clinical Trial

— EGN  

Official title:

A Two Year Multicentre, Randomized Two Arm Study Of Genotropin Treatment In Very Young Children Born Small For Gestational Age: Early Growth And Neurodevelopment(Egn)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00627523
• Other study ID #: A6281287
• Secondary ID: 2007-003949-32SG
• Status: Completed
• Phase: Phase 3
• First received: February 22, 2008
• Last updated: October 27, 2014
• Start date: February 2008
• Est. completion date: December 2013

Study information

• Verified date: October 2014
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To demonstrate the effect on height and psychomotor development of Growth Hormone treatment in very young children starting at an age of 2 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Months to 29 Months

Eligibility

Inclusion Criteria:

Caucasian male or female subjects aged between 19-29 months at Screening Visit 1.

Born SGA (birth length and/or weight <-2 SD for gestational age, using country-specific standards).

Height below -2.5 SD at screening (19-29 months of age). At least one measurement of length between 12 and 18 months of age. Normal karyotype in girls to exclude Turners syndrome.

Exclusion Criteria:

Severe Intra-Uterine Growth Retardation (IUGR) (birth length below - 4 SD for gestational age), if associated with dysmorphic features.

Severe prematurity (Gestational Age (GA) <32 weeks of gestation). Ongoing catch-up growth (defined as growth velocity SDS at inclusion >0) based on at least 4 months measurement interval).

Severe familial short stature defined as: Father's height below 155 cm or mother's height below 145 cm.

Defined neurological defects and/or severe neurodevelopmental delay.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Infant, Small for Gestational Age

Intervention

Drug:
• Genotropin (PN-180,307) Somatropin
Injectable Genotropin
• Control-no treatment
Control-no treatment

Locations

Country	Name	City	State
Belgium	Universitair Ziekenhuis Brussel/Pediatrie	Brussel
Belgium	Universitair Ziekenhuis Antwerpen / Pediatrie	Edegem
Czech Republic	Fakultni nemocnice Olomouc	Olomouc
Czech Republic	Fakultni nemocnice Ostrava, Detska klinika	Ostrava-Poruba
Czech Republic	Fakultni nemocnice v Motole	Praha 5
France	CHU Toulouse, Hôpital des Enfants, Service Endocrinologie	Toulouse Cedex 9
Germany	Universitaetsklinikum Erlangen, Kinder- und Jugendklinik	Erlangen
Italy	Centro di Endocrinologia Pediatrica, Dipartimento di Pediatria	Catania
Italy	Policlinico Universitario, Istituto di Clinica Pediatrica	Messina
Italy	Dipartimento Materno Infantile, UO di Pediatria e Neonatologia	Milano
Italy	Dipartimento di Medicina Pediatrica, UO di Endocrinologia e Diabetologia	Roma
Netherlands	Sophia Children's Hospital	Rotterdam
Spain	Hospital Virgen Del Camino	Pamplona	Navarra
Spain	Consorci Hospitalari Parc Tauli	Sabadell	Barcelona
Spain	Hospital Miguel Servet	Zaragoza
Sweden	Drottning Silvias Barn och Ungdomssjukhus	Göteborg
Switzerland	Inselspital	CH-3010 Bern

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

Belgium,  Czech Republic,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Height Standard Deviation Score (SDS) at Month 24.	Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.	Baseline and Month 24	No
Secondary	Change From Baseline in Growth Velocity SDS at Month 24.	The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.	Baseline and Month 24	No
Secondary	Change From Baseline in Height SDS at Month 12.	Height SDS was calculated at the relevant visit by means of the following formula: Height SDS = (participant height) - (normal height)/normal height standard deviation. Where participant height refers to the participant's height at the relevant visit, and normal height and the normal height standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for height SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. The scores were centred around zero. Negative score indicated a participant was smaller for their age/gender.	Baseline and Month 12	No
Secondary	Change From Baseline in Growth Velocity SDS at Month 12.	The growth velocity SDS was calculated at the relevant visit by means of the following formula: Growth velocity SDS = (participant growth velocity) - (normal growth velocity)/normal growth velocity standard deviation. Where, participant growth velocity refers to the participant's growth velocity at the relevant visit, and normal growth velocity and the normal growth velocity standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. The change from Baseline value for growth velocity SDS was calculated as the difference between the parameter values at a specific visit, and the Baseline parameter values. A negative score indicated that a participant had slower growth for their age/gender.	Baseline and Month 12	No
Secondary	Change From Baseline in Mental Development Using the Mental Development Index (MDI) of Bayley Scale at Month 12.	The Bayley Scale of Infant Development (BSID-II) measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the mental raw score which was used to calculate the MDI score. Possible MDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.	Baseline and Month 12	No
Secondary	Change From Baseline in Psychomotor Development Using the Psychomotor Development Index (PDI) of Bayley Scale at Month 12.	BSID-II measured the mental and psychomotor development and test behavior of participants from 1 to 42 months of age. The scale was used to describe the current developmental functioning of infants and to assist in diagnosis and treatment planning for infants with developmental delays or disabilities. The BSID-II provided the psychomotor raw score which was used to calculate the PDI score. Possible PDI scores ranged from 50-150. A score of 69 and below indicates significantly delayed performance, 70 to 84 indicates mildly delayed performance, 85 to 114 indicates normal limits and 115 and above indicates accelerated performance.	Baseline and Month 12	No
Secondary	Head Circumference SDS at Months 3, 6, 12, 18 and 24.	Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/ Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.	Months 3, 6, 12, 18 and 24	No
Secondary	Change From Baseline in Head Circumference SDS at Months 3, 6, 12, 18 and 24.	Head circumference SDS was calculated by means of the following formula = (Participant head circumference)-(Normal head circumference)/Normal head circumference standard deviation. Where participant head circumference refers to the participant's head circumference at the relevant visit, and normal head circumference and the normal head circumference standard deviation equals the population mean and standard deviation values for participants of a similar age and gender. A negative score indicated a participant had a smaller head circumference for their age/gender.	Baseline, Months 3, 6, 12, 18 and 24.	No
Secondary	Change From Baseline in Body Weight at Months 3, 6, 12, 18, and 24.	Body weight was measured at all the relevant visits. The change from Baseline in body weight was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.	Baseline, Months 3, 6, 12, 18, and 24	No
Secondary	Change From Baseline in Body Mass Index (BMI) at Months 3, 6, 12, 18, and 24.	Body mass index was calculated for all visits by means of the following formula: BMI (kg/m2) = Weight (kg)/(Height[m])2. The change from Baseline BMI was calculated as the difference between the parameter values at each visit, and the Baseline parameter values.	Baseline, Months 3, 6, 12, 18, and 24	No

External Links

•   To obtain contact information for a study center near you, click here.